- Open
- 0.14
- High
- 0.15
- Low
- 0.12
- Close
- 0.15
- Change
- -0.02 (-11.11%)
- Volume
- 69,396
| 15 Sept 2026 | 07:00:01 | Half-year Financial Report |
| 10 Aug 2026 | 07:00:06 | Cytolytix Patent Update |
| 17 Jul 2026 | 12:25:01 | Result of AGM, Warrants & Directorate Change |
| 22 Jun 2026 | 07:00:11 | Conclusion of Evaluation with University of Dundee |
| 4 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 18 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Valirx plc develops treatments for oncology and women's health, focusing on the transformation of scientific discoveries into clinical development. Its wholly owned subsidiary, Inaphaea Biolabs Limited, provides services related to patient-derived cell models, particularly in immune-oncology and breast cancer. Valirx generates revenue through service contracts and partnerships, leveraging its biobank and associated research capabilities. The company operates primarily in the United Kingdom and has expanded its reach to the United States through strategic collaborations.
| 15 Sept 2026 | 07:00:01 | Half-year Financial Report |
| 10 Aug 2026 | 07:00:06 | Cytolytix Patent Update |
| 17 Jul 2026 | 12:25:01 | Result of AGM, Warrants & Directorate Change |
| 22 Jun 2026 | 07:00:11 | Conclusion of Evaluation with University of Dundee |
| 4 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 18 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Valirx plc develops treatments for oncology and women's health, focusing on the transformation of scientific discoveries into clinical development. Its wholly owned subsidiary, Inaphaea Biolabs Limited, provides services related to patient-derived cell models, particularly in immune-oncology and breast cancer. Valirx generates revenue through service contracts and partnerships, leveraging its biobank and associated research capabilities. The company operates primarily in the United Kingdom and has expanded its reach to the United States through strategic collaborations.
| 22 Jun 2026 | 07:00:09 | Final Results & Notice of AGM |
| 27 May 2026 |
| ValiRX highlights Oncology opportunities and multi-application drug development pipeline |
| 15 May 2026 | AIM movers: Metals One uranium dump deal and Zinnwald Lithium recommends bid |
| 15 May 2026 | ValiRx shares drop 17% as life sciences group raises £1.16m at steep discount |
| 9 Jan 2026 | AIM movers: Pulsar Helium discovery and Galantas Gold profit taking |
| 5 Dec 2025 | AIM movers: Anglesey Mining financial restructuring and new iodine plant for Iofina |
| 30 Oct 2025 | AIM movers: Empire Metals premium fundraising and ex-dividends |
| 22 Jun 2026 | 07:00:09 | Final Results & Notice of AGM |
| 27 May 2026 |
| ValiRX highlights Oncology opportunities and multi-application drug development pipeline |
| 15 May 2026 | AIM movers: Metals One uranium dump deal and Zinnwald Lithium recommends bid |
| 15 May 2026 | ValiRx shares drop 17% as life sciences group raises £1.16m at steep discount |
| 9 Jan 2026 | AIM movers: Pulsar Helium discovery and Galantas Gold profit taking |
| 5 Dec 2025 | AIM movers: Anglesey Mining financial restructuring and new iodine plant for Iofina |
| 30 Oct 2025 | AIM movers: Empire Metals premium fundraising and ex-dividends |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £311m | +0.2% | |
| £282m | -0.2% | |
| £889k | +0.1% | |
| £741k | -0.2% | |
VALValirx plc | £562k | -0.7% |
| £342k | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £311m | +0.2% | |
| £282m | -0.2% | |
| £889k | +0.1% | |
| £741k | -0.2% | |
VALValirx plc | £562k | -0.7% |
| £342k | -0.8% |